Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Vape Flavor Ban Reversal; FDA Approves Sickle Cell Drug; FTC Clears BMS–Celgene Merger
November 18, 2019 – AJMC Staff
Is Carfilzomib an Appropriate Treatment Option for Patients With Newly Diagnosed Multiple Myeloma?
November 12, 2019 – Maggie L. Shaw
Treating Facility, Provider Patient Volume and Sharing Influence Survival of MM Patients
November 09, 2019 – Maggie L. Shaw
What We're Reading: Gilead Sued Over PrEP; Seasonal Workers and Medicaid; Preventable Deaths
November 08, 2019 – AJMC Staff
Blood Condition That Precedes Myeloma Presents Improved Chance for Early Treatment
November 06, 2019 – Allison Inserro
CMS, CMMI Seek Feedback on Oncology Care First, Successor to OCM
November 03, 2019 – Mary Caffrey
Top 5 AJMC® Articles of October 2019
November 01, 2019
Quadruple Therapy for Newly Diagnosed Patients With MM Shows PFS Benefit Over Triple Therapy
October 28, 2019 – Allison Inserro
What Contributes to Delayed Engraftment After Autologous Hematopoietic Cell Transplantation?
October 24, 2019 – Allison Inserro

What We're Reading: Vape Flavor Ban Reversal; FDA Approves Sickle Cell Drug; FTC Clears BMS–Celgene Merger

AJMC Staff
After saying he would back a ban on flavored vapes, President Trump now says he wants to study the issue more; the FDA approved Novartis’ crizanlizumab (Adakveo) as both monotherapy and in combination for patients 16 years or older with sickle cell disease; the Federal Trade Commission will allow Bristol-Myers Squibb to purchase Celgene for $74 billion in cash and stocks.

Trump Backs Away From Ban on Vape Flavors

With more than 40 deaths now on record caused by vaping and increasing reports of severe lung injuries, support rose for a ban on flavored e-cigarettes. After saying he would back such a ban, President Trump now says he wants to study the issue more, according to The New York Times. His advisors warned that moving forward with the restrictions could cost him votes and support.



FDA Approves New Drug to Treat Sickle Cell Disease

The FDA approved Novartis’ crizanlizumab (Adakveo) as both monotherapy and in combination for patients aged 16 and older with sickle cell disease (SCD). The monthly infusion is estimated to cost between $85,000 and $113,000, the Associated Press reported. Study results show that patients taking Adakveo for 1 year had just 1.6 pain episodes (or a 50% drop in sickle cell pain episodes) related to their SCD and 36% had none, compared with current treatments glutamine (Endari; 25%) and hydroxyurea (50%). However, both of the latter don’t work, or even stop working, in some patients; their dosing is also more complicated.

 

Bristol-Myers Squibb/Celgene Merger Given the Go-Ahead

On the condition that they sell apremilast (Otezla)–which will become the largest divestiture on record—the Federal Trade Commission will allow Bristol-Myers Squibb to purchase Celgene for $74 billion in cash and stocks, in what Reuters is calling “the biggest pharmaceutical deal ever.” The deal is expected to close on November 20. Amgen, meanwhile, will purchase Otezla, a psoriasis drug, for $13.4 billion.

Related Articles

CMS Proposes Price Transparency Changes, Updates to Physician Fee Schedule
Celgene Sells Psoriasis Drug Otezla to Amgen for $13.4 Billion
Novel Biologic Therapies for Sickle Cell Disease Management
HHS Releases Rules to Promote Price Transparency and Empower Patient Decision Making
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up